SerOptix
Inc is a research and development-based biotechnology company
located in Woburn, Massachusetts. Biotechnology in the post-genomic
era has seen the refocusing of informatics technology onto molecular
discovery and molecular signature analysis of human disease. The
pharmaceutical industry has already recognized the value of molecular
target identification as evidenced by recent multi hundred million
dollar deals in this sector. SerOptix has established proprietary
technologies and systems for molecular target discovery through
identification of unique disease signatures based on the intrinsic
fluorescence properties of disease-related molecules. Although
disease-specific fluorescent signatures can be partly or completely
obscured by molecules common to all individuals, preclinical studies
at SerOptix have demonstrated methods designed to fractionate
and selectively measure "fluorophore" populations. Our
platform technology "Spectra-Molecular
Informatics" or 'SMI,'
encompasses these advances through a combination of spectroscopy,
biochemistry and informatics. The Company has successfully exploited
this technology to demonstrate the applicability of the intrinsic
fluorescence spectra-molecular signatures for diagnostics and
for the identification of disease-specific molecular targets.
SerOptix is building on this initial development to integrate
its novel molecular profiling tools, the INFLIT
systems with its comprehensive SMI platform. The combined technology
will be focused on a broad set of proprietary and pharmaceutical
industry-sponsored programs for molecular target identification
for drug discovery and diagnostic development efforts. The Company
is continuing to build its technology portfolio to further enhance
the power of its Spectra-Molecular-Informatics Platform to efficiently
extract high value knowledge from fluorescence-based molecular
profiling, and support novel drug discovery and diagnostics development.
The Company foresees near term revenue from partner sponsored
studies, and the licensing of early stage SMI results. SerOptix
is raising capital to rapidly build business opportunities based
on this technology. Our business model, projects profitability
within a short time frame, and sustainable growth in subsequent
years from multiple R&D partnerships and the later stage outlicensing
of proprietary programs.
The
Company plans to execute the following strategy:
- Integrate
novel INFLIT instrumentation and INFLIT systems with the core
SMI platform and establish intellectual property protection
for this new technology.
-
Exploit these technologies for revenue, obtained through marketing
partnerships with instrument and systems providers to meet their
critical client needs in functional genomics, labile product
analysis and other biotechnology and product assurance applications.
- Utilize
this foundation to engineer an enhanced and comprehensive SMI
platform based on intrinsic fluorescence and complete the development
and establishment of a proprietary normal database of Spectra-Molecular
signatures and complement the Company's discovery paradigms
with subscription-based revenue built on the value of its proprietary
databases
- Direct
the power of SMI and its database to the identification of disease
candidates, including specific degenerative & metabolic diseases
and cancers in order to define disease-specific molecular targets
for licensing and co-development with corporate partners.
- Develop
selected SMI applications to advance high value drug discovery
and diagnostic projects funded by industry partners. Receive
with enhanced revenues based on client validation and leverage
successful partnerships to increase future project revenues.
- Expand
the research and development capacity of the Company and to
enhance SerOptix' ability to participate in government sponsored
R&D initiatives by establishing academic partnerships through
SerOptix-sponsored SMI research programs.
- Continue
to aggressively build an intellectual property portfolio that
protects the Company's innovations. The U.S. Patent and Trademark
Office has already issued the company two patents and additional
U.S. applications covering specific methodologies and applications
of the SMI Platform are being pursued.
[
About SerOptix ] [ The
SerOptix Process ]
[ Investment News ] [ Industry
News ] [ Media ]
[ Career Opportunities ] [ Contact
Us ][ Home ]
Copyright©
2000 SerOptix,Inc
All Rights Reserved
